United Therapeutics (UTHR) Competitors $290.91 +3.56 (+1.24%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$292.50 +1.59 (+0.55%) As of 09:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock UTHR vs. ALNY, BIIB, INCY, NBIX, EXEL, BMRN, EXAS, RGEN, HALO, and MDGLShould you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. United Therapeutics vs. Its Competitors Alnylam Pharmaceuticals Biogen Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Do analysts rate ALNY or UTHR? Alnylam Pharmaceuticals presently has a consensus target price of $340.00, indicating a potential upside of 5.57%. United Therapeutics has a consensus target price of $386.15, indicating a potential upside of 32.74%. Given United Therapeutics' higher probable upside, analysts clearly believe United Therapeutics is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.79United Therapeutics 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.69 Does the media refer more to ALNY or UTHR? In the previous week, United Therapeutics had 5 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 30 mentions for United Therapeutics and 25 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.08 beat United Therapeutics' score of 1.03 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 14 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 19 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ALNY or UTHR? Alnylam Pharmaceuticals has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Do institutionals & insiders believe in ALNY or UTHR? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 1.2% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable earnings and valuation, ALNY or UTHR? United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B18.68-$278.16M-$2.09-154.10United Therapeutics$2.88B4.56$1.20B$25.0611.61 Is ALNY or UTHR more profitable? United Therapeutics has a net margin of 40.44% compared to Alnylam Pharmaceuticals' net margin of -11.49%. United Therapeutics' return on equity of 19.33% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-11.49% -510.31% -6.48% United Therapeutics 40.44%19.33%16.73% SummaryUnited Therapeutics beats Alnylam Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition Export to ExcelMetricUnited TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.96B$2.43B$5.48B$8.94BDividend YieldN/A1.79%5.38%4.12%P/E Ratio11.618.7826.2219.74Price / Sales4.56636.32394.92109.12Price / Cash10.12154.3736.4957.06Price / Book2.024.467.915.37Net Income$1.20B$31.16M$3.15B$248.34M7 Day Performance1.73%0.38%0.75%1.67%1 Month Performance-10.62%8.14%3.46%4.56%1 Year Performance-8.24%3.02%34.60%18.42% United Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics4.9941 of 5 stars$290.91+1.2%$386.15+32.7%-8.8%$12.96B$2.88B11.611,305Positive NewsAnalyst ForecastALNYAlnylam Pharmaceuticals4.2888 of 5 stars$313.13+1.1%$319.58+2.1%+32.4%$40.83B$2.25B-149.822,230Positive NewsAnalyst ForecastBIIBBiogen4.9742 of 5 stars$124.76-1.8%$188.19+50.8%-43.9%$18.28B$9.68B12.327,605INCYIncyte4.3669 of 5 stars$67.26-1.8%$74.53+10.8%+12.9%$13.02B$4.41B210.192,617NBIXNeurocrine Biosciences4.9388 of 5 stars$125.80-0.6%$162.00+28.8%-8.6%$12.45B$2.36B42.641,800Positive NewsEXELExelixis4.7384 of 5 stars$43.37+7.4%$41.00-5.5%+96.0%$11.83B$2.17B19.711,147Positive NewsAnalyst ForecastGap UpHigh Trading VolumeBMRNBioMarin Pharmaceutical4.9455 of 5 stars$54.08-1.7%$93.45+72.8%-31.6%$10.37B$2.95B20.103,040EXASExact Sciences4.8814 of 5 stars$52.54-0.9%$70.90+34.9%+28.7%$9.91B$2.76B-9.547,000Analyst RevisionRGENRepligen4.7966 of 5 stars$120.11+1.1%$173.25+44.2%+2.5%$6.75B$634.44M-266.911,778Positive NewsAnalyst DowngradeHALOHalozyme Therapeutics4.8482 of 5 stars$52.800.0%$61.90+17.2%+1.7%$6.51B$1.02B14.04390Analyst RevisionMDGLMadrigal Pharmaceuticals3.9702 of 5 stars$282.99-1.0%$420.63+48.6%+7.5%$6.28B$180.13M-15.6890 Related Companies and Tools Related Companies ALNY Alternatives BIIB Alternatives INCY Alternatives NBIX Alternatives EXEL Alternatives BMRN Alternatives EXAS Alternatives RGEN Alternatives HALO Alternatives MDGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UTHR) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
